Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

erdafitinib

(ER-duh-FIH-tih-nib)
A drug used to treat adults with urothelial cancer (a type of bladder or urinary tract cancer) that has spread and has an abnormal FGFR3 gene. It is used in patients whose cancer got worse during or after treatment with at least one type of systemic therapy. It is also being studied in the treatment of other types of cancer. Erdafitinib blocks a protein called FGFR, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called Balversa.
Search NCI's Dictionary of Cancer Terms